Equities Analysts Issue Forecasts for Insmed Q2 Earnings

Insmed, Inc. (NASDAQ:INSM) – HC Wainwright boosted their Q2 2026 earnings per share estimates for Insmed in a note issued to investors on Thursday, March 26th. HC Wainwright analyst A. Fein now expects that the biopharmaceutical company will earn ($1.00) per share for the quarter, up from their previous estimate of ($1.05). HC Wainwright currently has a “Buy” rating and a $245.00 target price on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed’s Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.58) EPS, FY2027 earnings at $0.22 EPS, FY2028 earnings at $2.40 EPS, FY2029 earnings at $6.01 EPS and FY2030 earnings at $10.09 EPS.

Other equities research analysts also recently issued research reports about the company. Citigroup reissued an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Wolfe Research set a $167.00 price target on shares of Insmed and gave the stock an “outperform” rating in a research report on Thursday, December 18th. Royal Bank Of Canada lifted their price objective on shares of Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Leerink Partners boosted their price objective on shares of Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a report on Tuesday, March 24th. Finally, TD Cowen set a $241.00 target price on shares of Insmed in a research report on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Insmed has an average rating of “Buy” and a consensus target price of $210.19.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $145.30 on Monday. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. The firm has a market cap of $31.32 billion, a price-to-earnings ratio of -22.67 and a beta of 1.13. The stock’s fifty day moving average price is $150.13 and its two-hundred day moving average price is $166.24. Insmed has a one year low of $60.40 and a one year high of $212.75.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The firm had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.Insmed’s revenue for the quarter was up 152.6% on a year-over-year basis. During the same quarter last year, the business posted ($1.32) EPS.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 19,215 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00. Following the transaction, the chief executive officer owned 306,891 shares of the company’s stock, valued at approximately $51,864,579. The trade was a 5.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total value of $15,293,208.00. Following the completion of the transaction, the insider directly owned 41,754 shares in the company, valued at approximately $7,315,300.80. This represents a 67.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 189,651 shares of company stock worth $31,533,654 in the last 90 days. Company insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Insmed

A number of hedge funds have recently made changes to their positions in the business. Choreo LLC purchased a new stake in Insmed during the second quarter worth about $227,000. State Board of Administration of Florida Retirement System boosted its stake in Insmed by 245.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 130,165 shares of the biopharmaceutical company’s stock valued at $13,100,000 after acquiring an additional 92,533 shares during the last quarter. Norges Bank bought a new position in shares of Insmed during the 2nd quarter valued at approximately $194,728,000. New York State Common Retirement Fund increased its stake in shares of Insmed by 20.2% during the 2nd quarter. New York State Common Retirement Fund now owns 427,753 shares of the biopharmaceutical company’s stock worth $43,049,000 after purchasing an additional 72,031 shares during the last quarter. Finally, Edgestream Partners L.P. purchased a new stake in shares of Insmed during the 2nd quarter worth approximately $429,000.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.